Andrew J. Ritter
Vorstandsvorsitzender bei Docbot, Inc.
Profil
Andrew J.
Ritter was the founder of Ritter Pharmaceuticals, Inc. founded in 2004, where he held the title of President, Chief Executive Officer & Director from 2012 to 2014.
Currently, he is the Chief Executive Officer at Docbot, Inc. since 2021 and a Director at Myosin Therapeutics, Inc. since 2021.
In the past, he was a Commissioner at City of Los Angeles (California) from 2000 to 2002, and held the title of Managing Partner at Stonehenge Partners LLC and President at Ritter Natural Sciences LLC.
Mr. Ritter's education includes an undergraduate degree from the University of Southern California, an MBA from The Wharton School of the University of Pennsylvania, and an undergraduate degree from Stanford Graduate School of Business.
Aktive Positionen von Andrew J. Ritter
| Unternehmen | Position | Beginn |
|---|---|---|
Docbot, Inc.
 Docbot, Inc. Packaged SoftwareTechnology Services Docbot, Inc. operates as a health informatics company. The frim focuses on real-time applications of artificial intelligence for colonoscopy. The company was founded by William Karnes, Andrew Ninh and Tyler Dao and is headquartered in Irvine, CA. | Vorstandsvorsitzender | 24.05.2021 |
Myosin Therapeutics, Inc.
 Myosin Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Myosin Therapeutics, Inc. develops novel medications that target cellular motor proteins. The American company was founded in 2020 by Patrick R. Griffin, Theodore Kamenecka, Courtney A. Miller. | Direktor/Vorstandsmitglied | 01.10.2021 |
Ehemalige bekannte Positionen von Andrew J. Ritter
| Unternehmen | Position | Ende |
|---|---|---|
| City of Los Angeles (California) | Corporate Officer/Principal | 01.01.2002 |
| Ritter Natural Sciences LLC | Präsident | - |
Stonehenge Partners LLC
 Stonehenge Partners LLC Real Estate DevelopmentFinance Stonehenge Partners LLC provides real estate development services. The firm owns and operates residential, commercial, and retail properties in New York. The company was incorporated on December 2, 1997 and is headquartered in New York, NY. | Corporate Officer/Principal | - |
| QUALIGEN THERAPEUTICS, INC. | Gründer | - |
Ausbildung von Andrew J. Ritter
| University of Southern California | Undergraduate Degree |
| Stanford Graduate School of Business | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 6 |
|---|---|
Ritter Pharmaceuticals, Inc.
 Ritter Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ritter Pharmaceuticals, Inc. engages in the development of novel therapeutic products which modulate the human gut microbiome to treat digestive disorders and gastrointestinal diseases. It focuses on the development and commercialization of RP-G28. The company was founded by Andrew J. Ritter and Ira E. Ritter on March 29, 2004 and is headquartered in Los Angeles, CA. | Health Technology |
| City of Los Angeles (California) | Government |
Stonehenge Partners LLC
Stonehenge Partners LLC Real Estate DevelopmentFinance Stonehenge Partners LLC provides real estate development services. The firm owns and operates residential, commercial, and retail properties in New York. The company was incorporated on December 2, 1997 and is headquartered in New York, NY. | Finance |
| Ritter Natural Sciences LLC | |
Docbot, Inc.
Docbot, Inc. Packaged SoftwareTechnology Services Docbot, Inc. operates as a health informatics company. The frim focuses on real-time applications of artificial intelligence for colonoscopy. The company was founded by William Karnes, Andrew Ninh and Tyler Dao and is headquartered in Irvine, CA. | Technology Services |
Myosin Therapeutics, Inc.
Myosin Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Myosin Therapeutics, Inc. develops novel medications that target cellular motor proteins. The American company was founded in 2020 by Patrick R. Griffin, Theodore Kamenecka, Courtney A. Miller. | Commercial Services |
